Janssen Persuades Advisory Committee That Simeprevir Doesn’t Need Contraindication
Executive Summary
Janssen presents different analysis than FDA and appears to calm fears of a lack of efficacy in Hep C patients with the Q80K polymorphism.
You may also be interested in...
Janssen’s Simeprevir May Require Hep C Subpopulation Screening
FDA advisory committee briefing documents recommend patients be screened for the Q80K polymorphism because of lower efficacy in those patients, an issue not seen with Incivek or Victrelis.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.